Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Rankning i aktier #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Aktiekurs
$1,133.97
Senast synkroniserad: 2026-09-15
Marknadsvärde
$1.068T
Förändring (1 dag)
-0.39%
Förändring (1 år)
48.29%
Land
US
Handel Eli Lilly and Company (LLY)

Kategori

Antal utestående aktier för Eli Lilly and Company (LLY)
Antal utestående aktier per June 2026: 892.40M
Enligt de senaste finansiella rapporterna och aktiekursen för Eli Lilly and Company är det aktuella antalet utestående aktier 892.40M. I slutet av December 2024 hade företaget 900.61M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Eli Lilly and Company (LLY) från 2000 till 2026
Utestående aktier vid slutet av varje år
År Utestående aktier Ändra
2026 (TTM) 892.40M -0.62%
2025 898.00M -0.29%
2024 900.61M 0.14%
2023 899.38M -5.35%
2022 950.18M -0.36%
2021 953.65M -0.31%
2020 956.59M -0.10%
2019 957.53M -6.83%
2018 1.03B -2.31%
2017 1.05B -4.44%
2016 1.10B -0.40%
2015 1.11B -0.48%
2014 1.11B -0.55%
2013 1.12B -2.59%
2012 1.15B 2.92%
2011 1.11B 0.74%
2010 1.11B 0.68%
2009 1.10B 0.35%
2008 1.09B 0.37%
2007 1.09B 0.33%
2006 1.09B -0.08%
2005 1.09B 0.35%
2004 1.08B 0.74%
2003 1.08B -0.27%
2002 1.08B 0.12%
2001 1.08B -0.28%
2000 1.08B 0.00%
Utestående aktier för liknande företag eller konkurrenter
Företag Utestående aktier Skillnad Land
2.44B 173.44%
US
1.77B 98.45%
US
796.00M -10.80%
CH
0.00 -100.00%
US
1.91B 114.37%
CH